COR
Neutral signal
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Supports a bullish reading. 3 purchase disclosures year to date
- Financial indicators Pulls against a bullish reading. Current ratio 0.90 · operating margin 1.1%
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. Weekly bias is flat
VENTE TOTALE: 1 280 titres (~411 264,00 $ US)
- Insiders
- GREENBERG LON R
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$411,264
Avg sell (VWAP, 90d window) $323.98 vs last close $309.87 (-4.4%)
- Last activity
- 2026-09-16
- Liquidity
- Liquid $388,673,117/day · 20d vol
- Last synced
-
2026-09-24 21:10:18
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-16 | GREENBERG LON R | Sell | 1,280 | $321.30 | $411,264 | Form 4 |
| 2026-09-01 | Krikorian Lazarus | Sell | 985 | $325.97 | $321,080 | Form 4 |
| 2026-08-24 | Campbell Elizabeth S | Sell | 11,300 | $324.12 | $3,662,663 | Form 4 |
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Neutral signalScored 2026-09-21
COR presents a deeply concerning financial profile with razor-thin margins, a current ratio below 1.0, and a dangerously low quick ratio (~0.55), leaving virtually no buffer against short-term liquidity shocks.
The first sentence of the analysis written for COR on 2026-09-21 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 3.2% | 3.0% | 3.0% | 3.2% | 2.9% | |
| Ebit Margin | 0.8% | 0.8% | 0.9% | 1.0% | 1.1% | |
| Ebitda Margin | 1.2% | 1.1% | 1.3% | 1.3% | 1.4% | |
| Operating Profit Margin | 1.1% | 1.0% | 0.9% | 1.2% | 1.3% | |
| Pretax Profit Margin | 0.7% | 0.7% | 0.8% | 0.9% | 1.0% | |
| Continuous Operations Profit Margin | 0.5% | 0.5% | 0.7% | 0.7% | 0.7% | |
| Net Profit Margin | 0.5% | 0.5% | 0.7% | 0.7% | 0.7% | |
| Bottom Line Profit Margin | 0.5% | 0.5% | 0.7% | 0.7% | 0.7% | |
| Current Ratio | 0.903 | 0.879 | 0.876 | 0.911 | 0.938 | |
| Quick Ratio | 0.549 | 0.529 | 0.519 | 0.518 | 0.567 | |
| Solvency Ratio | 0.035 | 0.040 | 0.044 | 0.042 | 0.036 | |
| Cash Ratio | 0.076 | 0.060 | 0.055 | 0.081 | 0.062 | |
| Price To Earnings Ratio | 38.969 | 29.616 | 20.878 | 16.605 | 15.969 | |
| Price To Earnings Growth Ratio | 7.052 | -2.503 | 3.620 | 1.854 | -0.110 | |
| Forward Price To Earnings Growth Ratio | 7.052 | -2.503 | 3.620 | 1.854 | -0.110 | |
| Price To Earnings Diluted Ratio | 39.263 | 29.891 | 21.098 | 16.832 | 16.164 | |
| Price To Earnings Diluted Growth Ratio | 6.876 | -2.550 | 3.462 | 1.914 | -0.112 | |
| Price To Book Ratio | 40.168 | 69.169 | 70.536 | -133.355 | 110.126 | |
| Price To Sales Ratio | 0.189 | 0.152 | 0.140 | 0.118 | 0.115 | |
| Price To Free Cash Flow Ratio | 18.887 | 14.905 | 10.663 | 12.785 | 11.038 | |
| Price To Operating Cash Flow Ratio | 15.632 | 12.822 | 9.414 | 10.437 | 9.224 | |
| Debt To Assets Ratio | 0.140 | 0.099 | 0.109 | 0.134 | 0.153 | |
| Debt To Equity Ratio | 7.127 | 10.299 | 13.062 | -35.875 | 39.183 | |
| Debt To Capital Ratio | 0.877 | 0.912 | 0.929 | 1.029 | 0.975 | |
| Long Term Debt To Capital Ratio | 0.856 | 0.882 | 0.907 | 1.040 | 0.970 | |
| Financial Leverage Ratio | 50.789 | 103.883 | 119.844 | -267.352 | 256.713 | |
| Working Capital Turnover Ratio | -52.935 | -46.691 | -52.855 | -74.047 | -126.275 | |
| Operating Cash Flow Ratio | 0.067 | 0.064 | 0.080 | 0.062 | 0.064 | |
| Operating Cash Flow Sales Ratio | 0.012 | 0.012 | 0.015 | 0.011 | 0.012 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.828 | 0.860 | 0.883 | 0.816 | 0.836 | |
| Debt Service Coverage Ratio | 3.849 | 2.796 | 2.711 | 1.778 | 3.392 | |
| Interest Coverage Ratio | 8.690 | 12.225 | 8.875 | 11.862 | 14.654 | |
| Short Term Operating Cash Flow Coverage Ratio | 10.429 | 4.461 | 4.748 | 2.200 | 5.607 | |
| Operating Cash Flow Coverage Ratio | 0.361 | 0.524 | 0.574 | 0.356 | 0.305 | |
| Capital Expenditure Coverage Ratio | 5.801 | 7.153 | 8.533 | 5.446 | 6.085 | |
| Dividend Paid And Capex Coverage Ratio | 3.507 | 3.858 | 4.563 | 3.044 | 3.313 | |
| Dividend Payout Ratio | 0.281 | 0.276 | 0.228 | 0.231 | 0.238 | |
| Enterprise Value Multiple | 17.913 | 14.297 | 12.012 | 10.366 | 10.586 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 3.2% | ▲0.2% | ▲0.1% |
| Ebit Margin | 0.8% | ▲0.1% | ▼-0.1% |
| Ebitda Margin | 1.2% | ▲0.0% | ▼-0.1% |
| Operating Profit Margin | 1.1% | ▲0.1% | ▲0.0% |
| Pretax Profit Margin | 0.7% | ▲0.0% | ▼-0.1% |
| Continuous Operations Profit Margin | 0.5% | ▼-0.0% | ▼-0.1% |
| Net Profit Margin | 0.5% | ▼-0.0% | ▼-0.1% |
| Bottom Line Profit Margin | 0.5% | ▼-0.0% | ▼-0.1% |
| Current Ratio | 0.903 | ▲0.024 | ▲0.002 |
| Quick Ratio | 0.549 | ▲0.020 | ▲0.013 |
| Solvency Ratio | 0.035 | ▼-0.005 | ▼-0.004 |
| Cash Ratio | 0.076 | ▲0.017 | ▲0.009 |
| Price To Earnings Ratio | 38.969 | ▲9.353 | ▲14.561 |
| Price To Earnings Growth Ratio | 7.051 | ▲9.554 | ▲5.069 |
| Forward Price To Earnings Growth Ratio | 7.051 | ▲9.554 | ▲5.069 |
| Price To Earnings Diluted Ratio | 39.263 | ▲9.371 | ▲14.613 |
| Price To Earnings Diluted Growth Ratio | 6.875 | ▲9.425 | ▲4.958 |
| Price To Book Ratio | 40.168 | ▼-29.001 | ▲8.839 |
| Price To Sales Ratio | 0.189 | ▲0.036 | ▲0.046 |
| Price To Free Cash Flow Ratio | 18.887 | ▲3.982 | ▲5.232 |
| Price To Operating Cash Flow Ratio | 15.632 | ▲2.810 | ▲4.126 |
| Debt To Assets Ratio | 0.140 | ▲0.041 | ▲0.013 |
| Debt To Equity Ratio | 7.127 | ▼-3.172 | ▲0.368 |
| Debt To Capital Ratio | 0.877 | ▼-0.035 | ▼-0.067 |
| Long Term Debt To Capital Ratio | 0.856 | ▼-0.026 | ▼-0.075 |
| Financial Leverage Ratio | 50.789 | ▼-53.094 | ▼-1.987 |
| Working Capital Turnover Ratio | -52.935 | ▼-6.244 | ▲17.626 |
| Operating Cash Flow Ratio | 0.067 | ▲0.003 | ▼-0.001 |
| Operating Cash Flow Sales Ratio | 0.012 | ▲0.000 | ▼-0.001 |
| Free Cash Flow Operating Cash Flow Ratio | 0.828 | ▼-0.033 | ▼-0.017 |
| Debt Service Coverage Ratio | 3.849 | ▲1.053 | ▲0.944 |
| Interest Coverage Ratio | 8.690 | ▼-3.535 | ▼-2.571 |
| Short Term Operating Cash Flow Coverage Ratio | 10.430 | ▲5.968 | ▲4.940 |
| Operating Cash Flow Coverage Ratio | 0.360 | ▼-0.163 | ▼-0.063 |
| Capital Expenditure Coverage Ratio | 5.801 | ▼-1.352 | ▼-0.802 |
| Dividend Paid And Capex Coverage Ratio | 3.507 | ▼-0.351 | ▼-0.150 |
| Dividend Payout Ratio | 0.281 | ▲0.005 | ▲0.030 |
| Enterprise Value Multiple | 17.913 | ▲3.615 | ▲4.878 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $60.57B | $44.68B | $36.82B | $28.21B | $24.60B | |
| Enterprise value | $66.93B | $48.10B | $40.95B | $32.27B | $30.80B | |
| EV / Sales | 0.21x | 0.16x | 0.16x | 0.14x | 0.14x | |
| EV / Op. cash flow | 17.27x | 13.80x | 10.47x | 11.94x | 11.55x | |
| EV / Free cash flow | 20.87x | 16.05x | 11.86x | 14.62x | 13.82x | |
| EV / EBITDA | 17.91x | 14.30x | 12.01x | 10.37x | 10.59x | |
| Net debt / EBITDA | 1.70x | 1.02x | 1.21x | 1.30x | 2.13x | |
| Current ratio | 0.90x | 0.88x | 0.88x | 0.91x | 0.94x | |
| Income quality | 2.47x | 2.29x | 2.24x | 1.62x | 1.73x | |
| Graham number | $37 | $24 | $22 | — | $14 | |
| Graham net-net | -$213 | -$180 | -$170 | -$146 | -$159 | |
| Tax burden | 68.8% | 75.3% | 80.8% | 77.8% | 69.3% | |
| Interest burden | 84.3% | 89.0% | 88.7% | 90.4% | 92.4% | |
| Working capital | -$5.58B | -$6.56B | -$6.03B | -$3.89B | -$2.56B | |
| Invested capital | $15.96B | $10.08B | $11.13B | $12.03B | $14.96B | |
| Return on assets | 2.0% | 2.2% | 2.8% | 3.0% | 2.7% | |
| Operating ROA | 5.1% | 4.7% | 4.1% | 4.8% | 5.3% | |
| Return on tangible assets | 2.6% | 2.8% | 3.6% | 3.9% | 3.6% | |
| Return on equity | 103.1% | 233.6% | 334.3% | -803.0% | 689.5% | |
| Return on invested capital | 13.2% | 16.9% | 13.5% | 14.7% | 11.3% | |
| Return on capital employed | 19.4% | 23.7% | 17.8% | 21.0% | 16.7% | |
| Earnings yield | 2.6% | 3.4% | 4.7% | 6.0% | 6.3% | |
| Free cash flow yield | 5.3% | 6.7% | 9.4% | 7.8% | 9.1% | |
| Capex / Op. cash flow | 17.2% | 14.0% | 11.7% | 18.4% | 16.4% | |
| Capex / Depreciation | 62.5% | 108.7% | 46.7% | 69.9% | 85.1% | |
| Capex / Sales | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | |
| SG&A / Sales | 2.0% | 1.9% | 2.0% | 2.0% | 1.7% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 22.8% | 19.8% | 22.4% | 22.7% | 24.9% | |
| Days sales outstanding | 29d | 30d | 29d | 28d | 31d | |
| Days payables outstanding | 64d | 65d | 66d | 64d | 67d | |
| Operating cycle | 53d | 54d | 54d | 55d | 58d | |
| Cash conversion cycle | -11d | -11d | -12d | -8d | -8d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+35.6%EV / Sales ▲+27.3%EV / EBITDA ▲+25.3%EV / Op. cash flow ▲+3.468Earnings yield ▼-0.008Graham number ▲+13.874
Profitability
Return on equity ▼-1.306Return on assets ▼-0.002Return on invested capital ▼-0.037Return on capital employed ▼-0.043Operating ROA ▲+0.004Income quality ▲+0.178Tax burden ▼-0.065
Efficiency
Days sales outstanding ▼-0.988Days payables outstanding ▼-1.001Operating cycle ▼-1.262Cash conversion cycle ▼-0.260Capex / Sales +0.000R&D / Sales n/a
Balance-sheet strength
Current ratio ▲+0.024Net debt / EBITDA ▲+0.683Working capital ▲+977774000.000Invested capital ▲+5873924000.000Intangibles / Total assets ▲+0.029
Change over 5 years
Valuation
Market cap ▲+146.3%EV / Sales ▲+44.7%EV / EBITDA ▲+69.2%EV / Op. cash flow ▲+5.720Earnings yield ▼-0.037Graham number ▲+23.957
Profitability
Return on equity ▼-5.864Return on assets ▼-0.007Return on invested capital ▲+0.019Return on capital employed ▲+0.027Operating ROA ▼-0.002Income quality ▲+0.745Tax burden ▼-0.005
Efficiency
Days sales outstanding ▼-2.713Days payables outstanding ▼-2.609Operating cycle ▼-5.682Cash conversion cycle ▼-3.073Capex / Sales +0.000R&D / Sales n/a
Balance-sheet strength
Current ratio ▼-0.035Net debt / EBITDA ▼-0.432Working capital ▼-3025434000.000Invested capital ▲+995227000.000Intangibles / Total assets ▼-0.021
Employee count
Peer market caps
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-05-06 | Jared Moskowitz | Sale (Full) | $1,001 - $15,000 |
| 2026-05-06 | Jared Moskowitz | Sale (Full) | $1,001 - $15,000 |
| 2026-03-31 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2026-03-23 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2026-03-23 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2025-05-12 | Jefferson Shreve | Sale (Full) | $50,001 - $100,000 |
| 2025-03-27 | Greg Landsman | Sale (Full) | $15,001 - $50,000 |
| 2024-11-15 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-10-09 | Michael T. McCaul | Purchase | $15,001 - $50,000 |
| 2024-10-09 | Michael T. McCaul | Purchase | $50,001 - $100,000 |
| 2024-05-29 | Greg Landsman | Purchase | $15,001 - $50,000 |
| 2024-02-20 | Michael T. McCaul | Sale | $50,001 - $100,000 |
| 2024-02-20 | Michael T. McCaul | Sale | $1,001 - $15,000 |
| 2024-01-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-09-06 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-08-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-06-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-05-12 | Michael T. McCaul | Sale | $100,001 - $250,000 |
| 2023-05-12 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2023-03-24 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-03-14 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-02-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-01-25 | Diana Harshbarger | Purchase | $1,001 - $15,000 |
| 2023-01-25 | Diana Harshbarger | Purchase | $1,001 - $15,000 |
| 2023-01-25 | Diana Harshbarger | Purchase | $1,001 - $15,000 |
| 2023-01-11 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-01-05 | Michael T. McCaul | Sale | $100,001 - $250,000 |
| 2023-01-05 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2022-12-06 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-12-01 | Kurt Schrader | Purchase | $1,001 - $15,000 |
| 2022-10-07 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2022-10-07 | Michael T. McCaul | Sale | $50,001 - $100,000 |
| 2022-08-01 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-05-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-02-23 | Michael T. McCaul | Sale | $50,001 - $100,000 |
| 2022-02-23 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2019-06-24 | Donna Shalala | Sale (Full) | $1,001 - $15,000 |
Recent news
- 2026-09-21 Cencora Highlights Specialty Growth, MSO Expansion and Walgreens Ties at Conference Cencora (NYSE: COR) executives highlighted the company''s specialty pharmaceutical positioning, medical specialty organization strategy and capital-allocation priorities during an investor conference discussion, while reaffirming the durability of its relationship with Walgreens. Chief Executive Officer Bob Mauch said Cencora''s growth is being supported by pharmaceutical innovation, demographic trends and the company''s long-standing investments in specialty distribution and
- 2026-09-21 Cencora Highlights Specialty Growth, MSO Expansion and Walgreens Ties at Conference Cencora NYSE: COR executives highlighted the company''s specialty pharmaceutical positioning, medical specialty organization strategy and capital-allocation priorities during an investor conference discussion, while reaffirming the durability of its relationship with Walgreens.
- 2026-09-18 Here''s Why Cencora (COR) is a Strong Value Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here''s why you should take advantage.
- 2026-09-17 Corient Private Wealth LP Purchases 19,068 Shares of Cencora, Inc. $COR Corient Private Wealth LP lifted its holdings in Cencora, Inc. (NYSE: COR) by 102.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 37,601 shares of the company''s stock after buying an additional 19,068 shares during the period. Corient Private Wealth LP''s
- 2026-09-15 Cencora, Inc. (COR) Presents at 2026 Global Healthcare Conference Transcript Cencora, Inc. (COR) Presents at 2026 Global Healthcare Conference Transcript
- 2026-09-15 Cencora, Inc. (COR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Cencora, Inc. (COR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2026-09-15 3,733,921 Shares in Cencora, Inc. $COR Purchased by Bank of America Corp DE Bank of America Corp DE purchased a new position in shares of Cencora, Inc. (NYSE: COR) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 3,733,921 shares of the company''s stock, valued at approximately $1,056,625,000. Bank of
- 2026-09-14 AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? AbbVie is profitable, growing, and paying a rising dividend. CRISPR is burning cash in pursuit of a gene-editing breakthrough that could reshape medicine.
- 2026-09-10 Here''s Why Cencora (COR) is a Strong Momentum Stock Whether you''re a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 2026-09-08 Cencora, Inc. (COR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Cencora, Inc. (COR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript